Food allergy treatment market to reach USD 12.57 billion by 2032: How does CAGR of 8.62% impact investments?
According to the latest industry research, the global food allergy treatment market was valued at USD 6.51 billion in 2024 and is poised to more than double, reaching USD 12.57 billion by 2032, growing at a CAGR of 8.62% during the forecast period from 2025 to 2032.
The growth of this market is
propelled by a significant uptick in food allergy cases worldwide, especially
among children, and by increased awareness and diagnostic rates. Advances in
immunotherapy, such as oral immunotherapy (OIT) and epicutaneous immunotherapy
(EPIT), along with wider accessibility of epinephrine auto-injectors, are
transforming the food allergy treatment landscape.
Get Ahead of Market Shifts: Request Your Sample Report! https://www.snsinsider.com/sample-request/7288
Market Dynamics: Drivers and Trends
- Increasing Incidence of Food Allergies
With rising
exposure to allergenic foods and lifestyle changes, the prevalence of food
allergies has surged globally. Children are most affected, leading to increased
demand for preventive and therapeutic interventions.
- Improved Access to Immunotherapy
The acceptance
and approval of novel therapies such as PALFORZIA (for peanut allergy) and
investigational treatments like VIASKIN Peanut have revolutionized long-term
allergy management.
- Regulatory Support and R&D Investment
Regulatory
frameworks supporting clinical trials, along with increasing investments by key
players in R&D, have boosted innovation. Companies are pursuing advanced
biologics and desensitization therapies to cater to unmet medical needs.
- Growing Awareness and Education Campaigns
Awareness
campaigns by health authorities and patient advocacy groups have improved
diagnosis rates and treatment access, especially in developed economies.
Key Takeaways – Food Allergy
Treatment Market
- Market Size (2024): USD 6.51 billion
- Projected Market Size (2032): USD 12.57
billion
- CAGR (2025–2032): 8.62%
- U.S. Market (2024): USD 2.39 billion
- U.S. Market Forecast (2032): USD 4.43
billion (CAGR: 8.06%)
- Prominent Therapies: Epinephrine,
Immunotherapy (PALFORZIA, VIASKIN), Antihistamines, Xolair
- Top Segments by Allergen: Peanuts, Tree
Nuts, Shellfish, Dairy
- Route of Administration: Oral, Parenteral,
and Topical
- Distribution Channels: Hospital and Retail
Pharmacies
Regional Analysis
North America holds the largest
share of the food allergy treatment market, thanks to early adoption of
immunotherapy treatments, high prevalence of food allergies, and strong
healthcare infrastructure. The U.S. market alone is projected to reach USD 4.43
billion by 2032, supported by innovative therapies and proactive regulatory
support.
Europe follows closely, driven by
the expanding pharmaceutical pipeline and public awareness. Recent clinical
trials in countries like France, the UK, and Germany are pushing the boundaries
of therapeutic development.
Asia-Pacific is expected to
witness the fastest CAGR over the forecast period, with growing urbanization,
dietary shifts, and increasing diagnosis of allergies in countries such as
China, Japan, and India.
Latin America and the Middle East
& Africa markets are also emerging as high-potential regions due to
improvements in healthcare access and diagnostic services.
Demand for Market Analysis: Our Comprehensive Report
Offers Detailed Trends and Insights! https://www.snsinsider.com/reports/food-allergy-treatment-market-7288
Leading Market Players
The global food allergy treatment
landscape is dominated by both established pharmaceutical giants and innovative
biopharmaceutical startups. Key players include:
Food allergy treatment companies are Aimmune
Therapeutics, DBV Technologies, ALK-Abelló, Stallergenes Greer, Camallergy,
Alladapt Immunotherapeutics, Aravax, Intrommune Therapeutics, Prota Therapeutics,
Regeneron Pharmaceuticals, and other players.
These companies are actively
engaged in product development, strategic partnerships, and clinical research
to develop effective and accessible food allergy solutions.
Recent Developments in the
Market
- January 2025 – DBV Technologies announced
positive 24-month data from the Open-Label Extension (OLE) of its Phase 3
EPITOPE trial for VIASKIN Peanut 250 µg (VP250) in children aged 1 to 3
years. The data demonstrated sustained efficacy and improved desensitization
outcomes through 36 months of therapy, reinforcing the role of
epicutaneous immunotherapy in pediatric care.
Key Segmentation
By Allergen Type:
- Dairy Products
- Poultry Products
- Tree Nuts
- Peanuts
- Shellfish
- Wheat
- Soys
- Others
By Drug Type:
- Antihistamines
- Epinephrine
- Immunotherapy
- Xolair
- PALFORZIA
- Others
By Route of Administration:
- Oral
- Parenteral
- Topical
By End Use:
- Hospital Pharmacies
- Retail Pharmacies
- Others
Looking Ahead
The food allergy treatment market
is entering a new phase of growth, driven by advancements in immunotherapy,
growing awareness, and strong regulatory support. The expansion of oral and
skin-based desensitization therapies offers hope to millions of individuals and
families affected by food allergies.
With increasing R&D activity,
public-private collaborations, and an expanding patient population, the market
is well-positioned for continued innovation and sustained growth through 2032.
About Us:
SNS Insider is one of the leading
market research and consulting agencies that dominates the market research
industry globally. Our company's aim is to give clients the knowledge they
require in order to function in changing circumstances. In order to give you
current, accurate market data, consumer insights, and opinions so that you can
make decisions with confidence, we employ a variety of techniques, including
surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave - Vice President of
Client Engagement
Comments
Post a Comment